Journal of the Chinese Medical Association, 2022 Background: It is unclear whether hydroxymethylglutaryl-CoA reductase inhibitor (statin) therapy decreases the risk of mortality and cardiovascular disease (CVD) in patients undergoing peritoneal dialysis (PD).
Dan‐Ying Lee +5 more
openalex +2 more sources
Evaluating early administration of the hydroxymethylglutaryl-CoA reductase inhibitor simvastatin in the prevention and treatment of delirium in critically ill ventilated patients (MoDUS trial): study protocol for a randomized controlled trial [PDF]
Trials, 2015 BackgroundThe incidence of delirium in ventilated patients is estimated at up to 82%, and it is associated with longer intensive care and hospital stays, and long-term cognitive impairment and mortality.
Annalisa Casarin +9 more
openalex +2 more sources
Reduction of Brain β-Amyloid (Aβ) by Fluvastatin, a Hydroxymethylglutaryl-CoA Reductase Inhibitor, through Increase in Degradation of Amyloid Precursor Protein C-terminal Fragments (APP-CTFs) and Aβ Clearance [PDF]
Journal of Biological Chemistry, 2010 Chang‐Myung Oh +9 more
openalex +2 more sources
Diagnosis of Statin-Induced Necrotizing Myopathy: Contribution of Anti-HMGCR Antibodies
Acta Médica Portuguesa, 2022 Over the last few years, several cases of statin-induced necrotizing myopathy have been described. This myopathy is characterized by the necrosis of muscle fibers and the presence of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR ...
Cláudia Fidalgo +3 more
doaj +1 more source
Hydroxymethylglutaryl‐CoA reductase activity is essential for mitochondrial β‐oxidation of fatty acids to prevent lethal accumulation of long‐chain acylcarnitines in the mouse liver [PDF]
British Journal of PharmacologyStatins are competitive inhibitors of 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase (HMGCR), and exert adverse effects on mitochondrial function, although the mechanisms underlying these effects remain unclear.
Edgars Liepinsh +16 more
openalex +2 more sources
Exploring optimal Taxol® CYP725A4 activity in Saccharomyces cerevisiae [PDF]
, 2022 Background: CYP725A4 catalyses the conversion of the first Taxol® precursor, taxadiene, to taxadiene-5α-ol (T5α-ol) and a range of other mono- and di-hydroxylated side products (oxygenated taxanes). Initially known to undergo a radical rebound mechanism,
Lungang, L, Nowrouzi, B, Rios-Solis, L
core +1 more source
Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial: study protocol for a randomized controlled trial [PDF]
Trials, 2012 BackgroundAcute lung injury (ALI) is a common devastating clinical syndrome characterized by life-threatening respiratory failure requiring mechanical ventilation and multiple organ failure.
Daniel F. McAuley +9 more
openalex +2 more sources
Inhibition by the fungicide fenpropimorph of cholesterol biosynthesis in 3T3 fibroblasts [PDF]
Biochemical Journal, 1988 F Schuber +3 more
core +2 more sources